Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.33 better than the analyst estimate of $0.40. Revenue for the quarter came in at $135 million versus the consensus estimate of $127.25 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.